Shares
of Brainstorm Cell Therapeutics Inc. (Nasdaq: BCLI) rose 88 cents to close at $4.76 ahead of the
release of results from a Phase 2a clinical trial of its ALS treatment
NurOwn on Monday.
Brainstorm Cell Therapeutics rises ahead of results
December 31, 2014 at 16:26 PM EST
